SiBone (SIBN)
(Delayed Data from NSDQ)
$16.81 USD
+0.20 (1.20%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $17.10 +0.29 (1.73%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth D Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SIBN 16.81 +0.20(1.20%)
Will SIBN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for SIBN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SIBN
Si-Bone (SIBN) Reports Q1 Loss, Tops Revenue Estimates
Organon (OGN) Gears Up to Report Q1 Earnings: What's in Store?
SIBN: What are Zacks experts saying now?
Zacks Private Portfolio Services
What's in Store for DENTSPLY SIRONA (XRAY) in Q1 Earnings?
What's in Store for Cardinal Health (CAH) in Q3 Earnings?
Si-Bone (SIBN) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Other News for SIBN
SIBN Makes Bullish Cross Above Critical Moving Average
SI-BONE To Report Second Quarter 2024 Financial Results on August 5, 2024
SI-BONE To Present at Truist Securities 2024 MedTech Conference on June 18, 2024
Needham medtech/diagnostic analyst holds analyst/industry conference call
Needham medtech/diagnostic analyst holds analyst/industry conference call